European Medicines Agency

News and Video Search Results

News coverage

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

GlobeNewswire 02 May 2024

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

· New..

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
PR Newswire Asia 01 May 2024
Repligen Reports First Quarter 2024 Financial Results
GlobeNewswire 01 May 2024
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
GlobeNewswire 01 May 2024
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
GlobeNewswire 01 May 2024

0 shares 1 views

You might like

European Medicines Agency media coverage

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

GlobeNewswire 30 Apr 2024

Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) --..

EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
GlobeNewswire 30 Apr 2024
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
GlobeNewswire 30 Apr 2024
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
Accesswire 30 Apr 2024
Iovance Biotherapeutics to Present at Upcoming Conferences
GlobeNewswire 30 Apr 2024

Advertisement

More coverage

ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors

GlobeNewswire 30 Apr 2024

*ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors*

*Co-Founder of Spark Therapeutics..

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
GlobeNewswire 29 Apr 2024
MorphoSys AG Reports First Quarter 2024 Financial Results
EQS Group 29 Apr 2024
Liquid Handling Systems Market Size Worth $8.07 billion by 2031 at a CAGR of 7.8%: Straits Research
GlobeNewswire 29 Apr 2024
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
GlobeNewswire 29 Apr 2024